Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Med...
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Med...
Large-cap stocks saw worst performance last week, including MongoDB, Applovin, CAVA, Super Micro Computer, FTAI, Adobe, Ferguso...
SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 pe...
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compar...
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test...
Morgan Stanley analyst Sean Laaman assumes BeiGene (NASDAQ:BGNE) with a Overweight rating and announces Price Target of $300.
BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivot...
